Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity

AIDS Research and Human Retroviruses

Volumn 29, Issue 8, 2013, Pages 1117-1122

  Hsieh, Szu Min ^a   Pan, Sung Ching ^a   Chang, Sui Yuan ^a   Hung, Chien Ching ^a   Sheng, Wang Huei ^a   Chen, Mao Yuan ^a   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; SALVAGE THERAPY; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; TAIWAN; VIRUS REPLICATION;

EID: 84880545289     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0038     Document Type: Article

References (22)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed August 3, 2012.
2. Weinstock HS, Zaidi I, Heneine W, et al.. The epidemiology of antiretroviral drug resistance among drug-naive HIV-linfected persons in 10 US cities. J Infect Dis 2004;189. 2174-2180.
3. Wensing AMJ, van de Vijver DA, Angarano G, et al.. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe. Implications for clinical management. J Infect Dis 2005;192:958-966.
4. Lucas GM, Gallant JE, and Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 2004;18:1539-1548.
5. Gange SJ, Schneider MF, Grant RM, et al.. Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. J Acquir Immune Defic Syndr 2006;41:68-74.
6. Lawrence J, Mayers DL, Hullsiek KH, et al.. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003;49:837-846.
7. Deeks SG, Wrin T, Liegler T, et al.. Virologic and immunologic consequences of discontinuing combination antiretroviraldrug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-480.
8. Ledergerber B, the PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004;364:51-62.
9. Dauber DS, Ziermann R, Parkin N, et al.. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J Virol 2002;76:1359-1368.
10. Malim MH and Emerman M. HIV-1 sequence variation. Drift, shift, and attenuation. Cell 2001;104:469-472.
11. Lee MC, Deng J, Briggs JM, et al.. Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants. Biophys J 2005;88:3133-3146.
12. Hu Z and Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010;55:148-155.
13. De Luca A, Weidler J, Giambenedetto SD, et al.. Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. J Acquir Immune Defic Syndr 2007;45:411-417.
14. Guideline on HIV Diagnosis and Treatment, 3rd ed. Center for Disease Control, Taipei, ROC, 2010.
15. Chang SY, Chen MY, Lee CN, et al.. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 2008;61:689-693.
16. Lu J and Kuritzkes DR. A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants. J Acquir Immune Defic Syndr 2001;27:7-13.
17. Hu Z, Giguel F, Hatano H, et al.. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type J Virol 2006;80:7020-7027.
18. Johnson VA, Calvez V, Gunthard HF, et al.. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011;19:156-164.
19. Greene WC and Peterlin BM. Charting HIV's remarkable voyage through the cell. Basic science as a passport to future therapy. Nat Med 2002;8:673-680.
20. Bates M, Wrin T, Huang W, et al.. Practical applications of viral fitness in clinical practice. Curr Opin Infect Dis 2003; 16:11-18.
21. Nicastri E, Sarmati L, d'Ettorre G, et al.. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003;69:1-6.
22. Deeks SG. Non-nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001;26:S25-S33.